Cargando…

CSNK1E/CTNNB1 Are Synthetic Lethal To TP53 in Colorectal Cancer and Are Markers for Prognosis

Two genes are called synthetic lethal (SL) if their simultaneous mutations lead to cell death, but each individual mutation does not. Targeting SL partners of mutated cancer genes can kill cancer cells specifically, but leave normal cells intact. We present an integrated approach to uncovering SL pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tiong, Khong-Loon, Chang, Kuo-Ching, Yeh, Kun-Tu, Liu, Ting-Yuan, Wu, Jia-Hong, Hsieh, Ping-Heng, Lin, Shu-Hui, Lai, Wei-Yun, Hsu, Yu-Chin, Chen, Jeou-Yuan, Chang, Jan-Gowth, Shieh, Grace S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198690/ https://www.ncbi.nlm.nih.gov/pubmed/24947187 http://dx.doi.org/10.1016/j.neo.2014.04.007

Ejemplares similares

Synthetic lethality between TP53 and ENDOD1
por: Tang, Zizhi, et al.
Publicado: (2022)

Liver cancer with concomitant TP53 and CTNNB1 mutations: a case report
por: Friemel, Juliane, et al.
Publicado: (2016)

Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma
por: Chang, Jan-Gowth, et al.
Publicado: (2016)

Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand
por: Galy, Olivier, et al.
Publicado: (2011)

Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant TP53 or Wild-Type CTNNB1 Gene
por: Lin, Jiunn-Chang, et al.
Publicado: (2021)

Harnessing Synthetic Lethal Interactions for Personalized Medicine
por: Shieh, Grace S.
Publicado: (2022)

Frequency of somatic mutations in TERT promoter, TP53 and CTNNB1 genes in patients with hepatocellular carcinoma from Southern Italy
por: Lombardo, Daniele, et al.
Publicado: (2020)

Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinoma
por: Kumar, Sonu, et al.
Publicado: (2023)

Synthetic Lethal Drug Combinations Targeting Proteasome and Histone Deacetylase Inhibitors in TP53-Mutated Cancers
por: Das, Shaoli, et al.
Publicado: (2020)

Targeting Csnk1a1 in leukemia
por: Stegmaier, Kimberly
Publicado: (2014)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia
por: Järås, Marcus, et al.
Publicado: (2014)

Predictive functional, statistical and structural analysis of CSNK2A1 and CSNK2B variants linked to neurodevelopmental diseases
por: Unni, Prasida, et al.
Publicado: (2022)

CTNNB1 in neurodevelopmental disorders
por: Zhuang, Wenting, et al.
Publicado: (2023)

High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H
por: IMAI, HIROO, et al.
Publicado: (2014)

Tumor suppressor RBM24 inhibits nuclear translocation of CTNNB1 and TP63 expression in liver cancer cells
por: Moon, Sung Ung, et al.
Publicado: (2021)

CCND2, CTNNB1, DDX3X, GLI2, SMARCA4, MYC, MYCN, PTCH1, TP53, and MLL2 gene variants and risk of childhood medulloblastoma
por: Dahlin, Anna M., et al.
Publicado: (2015)

Transcriptomic Characterization of Hepatocellular Carcinoma with CTNNB1 Mutation
por: Ding, Xiao, et al.
Publicado: (2014)

The Role of CTNNB1 in Endometrial Cancer
por: Ledinek, Živa, et al.
Publicado: (2022)

Analysis of the Clinicopathologic Characteristics of Lung Adenocarcinoma With CTNNB1 Mutation
por: Zhou, Chao, et al.
Publicado: (2020)

Prognostic value and immunological role of CSNK1D in human cancers
por: Wang, Jianguo, et al.
Publicado: (2023)

ACLY facilitates colon cancer cell metastasis by CTNNB1
por: Wen, Jun, et al.
Publicado: (2019)

Redox-sensitive TP53INP1 SUMOylation as an oxidative stress sensor to activate TP53
por: Bonacci, Thomas, et al.
Publicado: (2014)

TP53 Status is Associated with Thrombospondin1 Expression In vitro
por: Alvarez Secord, Angeles, et al.
Publicado: (2013)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

CTNNB1 Mutation in Aldosterone Producing Adenoma
por: Wang, Jian-Jhong, et al.
Publicado: (2017)

CTNNB1 mutations are clonal in adamantinomatous craniopharyngioma
por: Apps, J. R., et al.
Publicado: (2020)

Recurrent CTNNB1 mutations in craniofacial osteomas
por: Baumhoer, Daniel, et al.
Publicado: (2021)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

CSNK2 in cancer: pathophysiology and translational applications
por: Strum, Scott W., et al.
Publicado: (2021)

Loss of CDYL Results in Suppression of CTNNB1 and Decreased Endometrial Receptivity
por: Zhou, Xiaowei, et al.
Publicado: (2020)

Csnk1a1 inhibition modulates the inflammatory secretome and enhances response to radiotherapy in glioma
por: Liu, Guanzheng, et al.
Publicado: (2021)

Compartmentalization of casein kinase 1 γ CSNK1G controls the intracellular trafficking of ceramide
por: Goto, Asako, et al.
Publicado: (2022)

Activating mutations in CTNNB1 in aldosterone producing adenomas
por: Åkerström, Tobias, et al.
Publicado: (2016)

The impact of chemotherapeutic drugs on the CYP1A1-catalysed metabolism of the environmental carcinogen benzo[a]pyrene: Effects in human colorectal HCT116 TP53(+/+), TP53(+/−) and TP53(−/−) cells
por: Willis, Alexandra J., et al.
Publicado: (2018)

Mechanisms of synthetic lethality between BRCA1/2 and 53BP1 deficiencies and DNA polymerase theta targeting
por: Ronson, George E., et al.
Publicado: (2023)

Explaining cancer type specific mutations with transcriptomic and epigenomic features in normal tissues
por: Tiong, Khong-Loon, et al.
Publicado: (2018)

MGSEA – a multivariate Gene set enrichment analysis
por: Tiong, Khong-Loon, et al.
Publicado: (2019)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

Haploinsufficiency Interactions of RALBP1 and TP53 in Carcinogenesis
por: Awasthi, Sanjay
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cd9vemngqm68abj7lc1laflbl0